Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Targeting Dysregulated Signaling in Glioblastoma Stem Cells to Develop New Personalized Treatments

EF 2024-25

Résumé
Glioblastomas are the most common and aggressive type of brain cancer. Despite the best treatments available (surgery, radiation, and chemotherapy), the majority of patients survive for just over one year before passing from this incurable disease. Presently, therapies fail to eliminate glioblastoma stem cells allowing them to grow uncontrollably and drive cancer relapse thus we must target these cancer stem cells to make any notable improvement in patient outcomes. Current research suggests that cancer stem cells in glioblastoma arise from dysfunctional stem cells from a unique region in the brain called the subventricular zone. During fetal development, stem cells from the subventricular zone were the origin of the human brain, but in cancer this developmental process is hijacked. Normally, molecular regulatory signals in the subventricular zone keep stem cell division tightly controlled but in glioblastoma, this regulation is disrupted. By comparing normal brain stem cells and cancer stem cells in their respective tissue environments, we have found key regulatory signals exploited by cancer stem cells for their survival. We hypothesize that therapies that target dysfunctional cancer stem cell signaling pathways will be effective for treating glioblastoma. We will test new treatments on glioblastoma organoids (miniature tumors) grown from patient tissues with the aim of restoring brain stem cell regulation. We will dissect the mechanism of successful treatments by genetically sequencing individual cells from these treated tumor organoids to understand changes in cell state and tumor interactions. Based on pre-clinical results the Petrecca Lab will be well poised to launch a clinical trial at The Neuro bringing us one step closer to robust treatments for glioblastoma.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530140
Name
Li Cheng Zhe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Dysregulated Signaling in Glioblastoma Stem Cells to Develop New Personalized Treatments
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Glioblastoma; Glioblastoma Stem Cells; Merfish In-Situ Spatial Transcriptomics; Neural Stem Cells; Patient-Derived Organoids; Personalized Medicine; Single-Cell Rna Sequencing; Subventricular Zone
Abstract
Glioblastomas are the most common and aggressive type of brain cancer. Despite the best treatments available (surgery, radiation, and chemotherapy), the majority of patients survive for just over one year before passing from this incurable disease. Presently, therapies fail to eliminate glioblastoma stem cells allowing them to grow uncontrollably and drive cancer relapse thus we must target these cancer stem cells to make any notable improvement in patient outcomes. Current research suggests that cancer stem cells in glioblastoma arise from dysfunctional stem cells from a unique region in the brain called the subventricular zone. During fetal development, stem cells from the subventricular zone were the origin of the human brain, but in cancer this developmental process is hijacked. Normally, molecular regulatory signals in the subventricular zone keep stem cell division tightly controlled but in glioblastoma, this regulation is disrupted. By comparing normal brain stem cells and cancer stem cells in their respective tissue environments, we have found key regulatory signals exploited by cancer stem cells for their survival. We hypothesize that therapies that target dysfunctional cancer stem cell signaling pathways will be effective for treating glioblastoma. We will test new treatments on glioblastoma organoids (miniature tumors) grown from patient tissues with the aim of restoring brain stem cell regulation. We will dissect the mechanism of successful treatments by genetically sequencing individual cells from these treated tumor organoids to understand changes in cell state and tumor interactions. Based on pre-clinical results the Petrecca Lab will be well poised to launch a clinical trial at The Neuro bringing us one step closer to robust treatments for glioblastoma.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Cheng Zhe
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~